A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.
Schaefer, G., Haber, L., Crocker, L.M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C.V., Stawicki, S., Clark, R., Fields, C., Lewis Phillips, G.D., Prell, R.A., Danilenko, D.M., Franke, Y., Stephan, J.P., Hwang, J., Wu, Y., Bostrom, J., Sliwkowski, M.X., Fuh, G., Eigenbrot, C.(2011) Cancer Cell 20: 472-486
- PubMed: 22014573 
- DOI: https://doi.org/10.1016/j.ccr.2011.09.003
- Primary Citation of Related Structures:  
3P0V, 3P0Y, 3P11 - PubMed Abstract: 
Extensive crosstalk among ErbB/HER receptors suggests that blocking signaling from more than one family member may be essential to effectively treat cancer and limit drug resistance. We generated a conventional IgG molecule MEHD7945A with dual HER3/EGFR specificity by phage display engineering and used structural and mutational studies to understand how a single antigen recognition surface binds two epitopes with high affinity ...